

UC Santa Cruz

UC Santa Cruz Previously Published Works

Title

IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC

Permalink

<https://escholarship.org/uc/item/784385x0>

Journal

Cell Reports, 15(9)

ISSN

2639-1856

Authors

Ennajdaoui, Hanane
Howard, Jonathan M
Sterne-Weiler, Timothy
et al.

Publication Date

2016-05-01


DOI

10.1016/j.celrep.2016.04.083

Peer reviewed

IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC

Graphical Abstract



Authors

Hanane Ennajaoui,
Jonathan M. Howard,
Timothy Sterne-Weiler, ...,
Benjamin J. Blencowe, Luiz O.F. Penalva,
Jeremy R. Sanford

Correspondence

jsanfor2@ucsc.edu

In Brief

IGF2BP3 is an onco-fetal RNA binding protein associated with a variety of malignant tumors. Ennajaoui et al. establish a role for IGF2BP3 in the regulation of an extensive post-transcriptional regulatory network associated with tumor cell migration via modulation of RISC-mRNA interactions.

Highlights

- IGF2BP3 promotes an invasive phenotype in pancreatic ductal adenocarcinoma cells
- IGF2BP3 regulates a malignancy-associated gene expression program in PDAC cells
- IGF2BP3 binding sites in PDAC cell lines are enriched near microRNA target sites
- IGF2BP3 modulates mRNA target association with Ago2

Accession Numbers

GSE79147



IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC

Hanane Ennajaoui,^{1,2} Jonathan M. Howard,¹ Timothy Sterne-Weiler,^{1,2} Fereshteh Jahanbani,^{1,6} Doyle J. Coyne,¹ Philip J. Uren,³ Marija Dargyte,¹ Sol Katzman,⁴ Jolene M. Draper,¹ Andrew Wallace,¹ Oscar Cazarez,¹ Suzanne C. Burns,⁵ Mei Qiao,⁵ Lindsay Hinck,¹ Andrew D. Smith,³ Masoud M. Toloue,⁷ Benjamin J. Blencowe,² Luiz O.F. Penalva,⁵ and Jeremy R. Sanford^{1,*}

¹Department of Molecular, Cellular and Developmental Biology, University of California Santa Cruz, 1156 High Street, Santa Cruz, CA 95060, USA

²The Donnelly Centre, University of Toronto, Toronto, ON M5S 1A1, Canada

³Molecular and Computational Biology Section, Division of Biological Sciences, University of Southern California, Los Angeles, CA 90089, USA

⁴Center for Biomolecular Science and Engineering, University of California Santa Cruz, 1156 High Street, Santa Cruz, CA 95060, USA

⁵Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

⁶Department of Genetics, Stanford University, 3165 Porter Drive, Palo Alto, CA 94304, USA

⁷Bioo Scientific Corporation, 7500 Burlestone Road, Austin, TX 78744, USA

*Correspondence: jsanford2@ucsc.edu

<http://dx.doi.org/10.1016/j.celrep.2016.04.083>

SUMMARY

Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) expression correlates with malignancy, but its role(s) in pathogenesis remains enigmatic. We interrogated the IGF2BP3-RNA interaction network in pancreatic ductal adenocarcinoma (PDAC) cells. Using a combination of genome-wide approaches, we have identified 164 direct mRNA targets of IGF2BP3. These transcripts encode proteins enriched for functions such as cell migration, proliferation, and adhesion. Loss of IGF2BP3 reduced PDAC cell invasiveness and remodeled focal adhesion junctions. Individual nucleotide resolution crosslinking immunoprecipitation (iCLIP) revealed significant overlap of IGF2BP3 and microRNA (miRNA) binding sites. IGF2BP3 promotes association of the RNA-induced silencing complex (RISC) with specific transcripts. Our results show that IGF2BP3 influences a malignancy-associated RNA regulon by modulating miRNA-mRNA interactions.

INTRODUCTION

RNA binding proteins (RBPs) and microRNAs (miRNAs) are the central mediators of post-transcriptional gene regulation (Gerstberger et al., 2014). Like transcription factors, RBPs and miRNAs coordinate expression of proteins with related functions (Blackinton and Keene, 2014; Keene, 2007). These regulatory factors often converge on the 3' UTRs of mRNAs (Jens and Rajewsky, 2015). Juxtaposition of their binding sites contributes to combinatorial mechanisms of post-transcriptional gene regulation (Glorian et al., 2011; Zhang et al., 2008; Kundu et al., 2012; Young et al., 2012; Kim et al., 2009; Jafarifar et al., 2011; Ho et al., 2013).

IGF2BP1, -2, and -3 are a family of structurally and functionally related RBPs with developmentally regulated expression patterns (Yaniv and Yisraeli, 2002). IGF2BP3 is of particular interest because it is undetectable in most adult tissue but strongly expressed in embryos and in diverse tumor types (Mueller-Pillasch et al., 1999; Köbel et al., 2009; Schaeffer et al., 2010; Findeis-Hosey and Xu, 2011). For example, it is upregulated in 90% of pancreatic ductal adenocarcinomas, suggesting that it may have a role in initiation or progression of cancer (Schaeffer et al., 2010). Several groups proposed that elevated IGF2BP3 expression is prognostic for malignancy in PDAC, colorectal, ovarian cancers, and B-acute lymphocytic leukemia (B-ALL) and negatively influences patient survival (Suvasini et al., 2011; Stoskus et al., 2011; Schaeffer et al., 2010; Lochhead et al., 2012; Köbel et al., 2009; Bell et al., 2013). Indeed, Taniuchi et al. demonstrated aberrant IGF2BP3 expression in pancreatic tumors promotes metastasis in xenograft assays in nude mice (Taniuchi et al., 2014). It is likely that this role of IGF2BP3 in cancer metastasis mirrors a normal function of IGF2BP3-mediated cell migration during embryogenesis (Mueller et al., 2003; Mueller-Pillasch et al., 1999).

The evidence for IGF2BP3 acting as a bona fide pathoprotein continues to mount (Wagner et al., 2003; Palanichamy et al., 2016), yet several fundamental questions remain unanswered. For example, IGF2BP3 regulates cytoplasmic steps of post-transcriptional gene expression, but the molecular mechanisms are unknown (Nielsen et al., 1999; Vikesaa et al., 2006; Jonson et al., 2014; Gu et al., 2012). Another challenge is elucidating the RNA binding specificity of IGF2BP3 in cancer cells. Recent studies identified transcripts associated with exogenous or endogenous IGF2BP3 using photo activated ribonucleoside (PAR)-CLIP and RIP-seq (Hafner et al., 2010; Taniuchi et al., 2014). Here, we use a combination of genomic approaches to discover cancer-related IGF2BP3 mRNA targets. These data also suggest a mechanism for IGF2BP3-dependent gene regulation. We find that IGF2BP3 modulates the association of target transcripts




Figure 1. IGF2BP3 Regulates Transcripts Associated with Cancer Pathways

(A) Volcano plot depicting differentially expressed genes from both PANC1 and PL45 (blue dots) and those mRNAs bound by IGF2BP3 (orange dots).

(B) Bar graph showing relative quantification of mRNA levels in IGF2BP3-depleted or control PANC1 cells.

(C) KEGG pathway enrichment analysis of differentially expressed-IGF2BP3 bound mRNAs (orange dots from A).

(D) Gene Ontology enrichment analysis of differentially expressed-IGF2BP3 bound mRNAs.

(E) Genome Browser snapshots of read coverage from replicate RIP-seq experiments from PL45 cells for CD44 and CLDN1 3' UTR (top and bottom, respectively).

(F) Relative quantification qRT-PCR analysis of CD44 and CLDN1 mRNA stability in control or IGF2BP3-depleted PL45 cells.

(G) Bar graph quantifying the invasiveness of control or IGF2BP3-depleted PANC1 or PL45 cells through Matrigel filters relative to control filters. Bars represent an average of three independent experiments. Error bars correspond to SD. Statistical significance was estimated using an unpaired t test (** $p < 0.001$, * $p < 0.05$).

over-represented for functions in focal adhesion junctions, cell migration, and regulation of the actin cytoskeleton (see Table S2). Included in this common set are *CD44*, *HMGA2*, *EIF4EBP2*, *ARF6*, and *ARHGEF4*, previously characterized as IGF2BP3 targets (Vikesaa et al., 2006; Jønson et al., 2014; Taniuchi et al., 2014; Mizutani et al., 2015)

To identify IGF2BP3 regulatory targets, we analyzed steady-state mRNA levels in IGF2BP3-depleted and control PDAC cells (PL45 and PANC1 cell lines) using high-throughput RNA sequencing (RNA-seq). Differential expression sequencing (DESeq) analysis revealed 2,795 differentially expressed PANC1 genes (Figure 1A; Table S3).

We validated several candidate genes from PANC1 cells by RT-qPCR. Of the 10 transcripts selected for validation, 9 agreed with the RNA-Seq data (Figure 1B). In PL45 cells, DESeq identified 137 differentially expressed transcripts (Table S3). We obtained similar results using Affymetrix exon arrays (Figure 1A; Table S4). Of the 137 differentially expressed genes in PL45 cells, 53 were also identified in the PANC1 experiment ($p < 0.0001$, Fisher's exact test). Comparison of control PANC1 and PL45 revealed thousands of differentially expressed genes, suggesting that these cell models are quite different (Table S5; Ryu et al., 2002) To identify direct IGF2BP3 regulatory targets, we focused on differentially expressed transcripts that are reproducibly associated with IGF2BP3 in RIP-seq assays (Figure 1A, orange dots). This approach revealed 164 transcripts encoding

with the RNA-induced silencing complex (RISC). Taken together, our results reveal a malignancy associated RNA network regulated by IGF2BP3.

RESULTS

Identification of IGF2BP3 mRNA Targets in PDAC Cells

To characterize the mRNA targets of IGF2BP3, we performed RIP-seq in two PDAC cell lines. We identified 2,223 and 1,718 transcripts enriched in the anti-IGF2BP3 immunoprecipitate relative to the control from PL45 and PANC1 cells, respectively (Figure S1; Table S1). A significant fraction of the PANC1 target transcripts (1,069, or ~63%; Figure S1D) were also identified in the PL45 RIP dataset (odds-ratio = 14.2, $p < 1.50e-195$, Fisher's exact test). This common set of transcripts encodes proteins




Figure 2. Global Single-Nucleotide-Resolution IGF2BP3-RNA Interaction Map

(A) Bar graph showing genomic distribution of IGF2BP3 from PDAC cell lines, hnRNPA1 (HEK293 cells), and simulated (hg19 background) crosslinking sites. The bars represent the average of replicate experiments ($n = 2$ from PL45; $n = 1$ from PANC1), respectively. SDs are indicated by error bars. (B) Distribution of peaks called from IGF2BP3-, hnRNPA1- and simulated crosslinking sites within mRNA. (C) Meta-analysis of IGF2BP3 and hnRNPA1 iCLIP crosslink sites relative to the stop codon. Relative crosslinking density (normalized count) is shown \pm SEM. (D) IGF2BP3 crosslinking density from PDAC cell lines mapped relative to annotated miRNA target sites. hnRNPA1 crosslinking sites from HEK293 cells are included as a control. (E) Overrepresented pentamers found near IGF2BP3 crosslinking sites in PDAC cells.

proteins enriched for functions in cancer pathways, cellular migration/motility, and regulation of the actin cytoskeleton (Figures 1C and 1D, adjusted $p < 0.05$; Table S2).

We investigated how IGF2BP3 affects steady-state mRNA levels using the PL45 cell model. In PL45 cells, as previously described for HeLa cells (Vikesaa et al., 2006), IGF2BP3-depletion correlates with reduced mRNA levels of the bona fide target CD44 (Tables S1 and S3). Previous studies determined that IGF2BP3 stabilizes CD44 mRNA (Vikesaa et al., 2006). We used actinomycin D to inhibit transcription and measure the decay rate of CD44 and three additional targets, ANTRX1, CLDN1, and OLR1 mRNAs. As expected, we confirmed that CD44 mRNA is less stable in IGF2BP3-depleted cells. Likewise, ANTRX1 mRNA also has a shorter half-life in IGF2BP3-depleted cells relative to control cells. By contrast, decay of CLDN1 and OLR1 mRNA is attenuated when IGF2BP3 is depleted from PL45 cells (Figures 1E and 1F).

IGF2BP3 Modulates Focal Adhesions and Promotes PDAC Cell Invasiveness

To determine how IGF2BP3 expression influences cancer cell biology, we analyzed focal adhesion junctions and cell migration in control or IGF2BP3-depleted PDAC cells (Figure S2). Genes from both of these pathways are enriched in the IGF2BP3-RNA

interaction network (Figures 1C and 1D; Table S2). We stained focal adhesion complexes with antibody recognizing focal adhesion kinase (FAK). Although FAK staining localizes to the periphery of both control and IGF2BP3-depleted cell lines, their size difference was significant in IGF2BP3-depleted cells relative to control (Figures S2D and S2E; $p < 0.0020$, Student's t test). To determine whether depletion of IGF2BP3 affects the invasive behavior of PDAC cells, we performed in vitro invasion assays. IGF2BP3-depleted cells exhibited significantly reduced invasiveness as compared to control cells (Student's t test, $p < 0.01$ for both lines; Figures 1G and S2C). Taken together, these data show that IGF2BP3 alters the focal adhesion junction and promotes PDAC invasiveness in vitro.

A Single-Nucleotide-Resolution Map of IGF2BP3-RNA Interactions

We used individual nucleotide resolution CLIP (iCLIP) to determine in situ binding specificity of IGF2BP3 in PL45 and PANC1 cells. Anti-IGF2BP3 antibodies precipitated nuclease-sensitive protein-RNA complexes from whole cell extracts of UV-irradiated cells (Figures S3A–S3C). We obtained three libraries from two replicate experiments from PL45 and a single PANC1 assay. We identified 244 and 124 mRNA targets that directly crosslinked with IGF2BP3 in PL45 and PANC1 cells, respectively (Table S6).




Figure 3. IGF2BP3 Modulates Expression of miRNA-Regulated Transcripts

(A) Examples of miRNA families with significant sequence similarity between their target site and the IGF2BP3 consensus motif (left panel). Enrichment of miRNA target sites in 3' UTRs identified by iCLIP and by RNA-seq analysis of control or IGF2BP3-depleted PANC1 cells.

(B) UCSC genome browser screen shots showing read coverage across miRNA-9 and -128 loci (top and bottom, respectively). Histogram shows number of reads at each position. Sequence conservation across 100 vertebrate genomes (navy blue track).

(C) Schematic diagram of luciferase reporter plasmids.

(D) Scatterplot showing normalized luciferase reporter expression (fold repression) in control cells (orange) and IGF2BP3-depleted cells (blue).

Unique reads from the IGF2BP3 iCLIP libraries map with high frequency to exonic sequences. This distribution differs from another RBP, hnRNPA1, which crosslinks to intronic sequences (Figure 2A). A background set of simulated crosslinking sites map primarily to intergenic regions (Figure 2A). We annotated IGF2BP3, hnRNPA1 and simulated binding sites using the Piranha peak caller software (Uren et al., 2012). Both IGF2BP3 and hnRNPA1 peaks occur with highest frequency in 3' UTRs of target transcripts (Figure 2B). By contrast, simulated data exhibit a larger proportion of peaks in first and internal exons.

IGF2BP3 binding sites occur frequently within 3' UTRs. We hypothesized that *cis*-regulatory signals associated with 3' UTR overlap IGF2BP3 binding sites. To test this hypothesis, we refined the IGF2BP3-RNA interaction map by isolating the 5' end of each read. These positions correspond to the protein-RNA crosslink site. We determined crosslinking frequency relative to *cis*-acting RNA elements within 3' UTRs (Figures 2C and 2D). IGF2BP3 and hnRNPA1 crosslinking density relative to stop codons is similar (Figure 3C). By contrast, crosslinking density for IGF2BP3, but not hnRNPA1, peaked within a 25-bp window centered on predicted miRNA target sequences (Figure 2D). These data suggest that IGF2BP3 binding is specifically enriched over predicted miRNA target sites. Next, we used IGF2BP3 crosslink sites to identify overrepresented motifs using a pentamer-clustering approach (see Experimental Procedures). Two overrepresented motifs occur within a 10-nt window of each crosslinking site. One motif resembles a previously defined IGF2BP3 consensus binding sequence (Figure 2E, bottom; Table S7; Hafner et al., 2010). Our results are also consistent with a bipartite motif described for IGF2BP1 (Chao et al., 2010). Approximately 50%–70% of the PL45 and PANC1 iCLIP targets significantly overlapped the RNA immunoprecipitation and high throughput sequencing (RIP-seq) data (Fisher's exact test $p < 2.74 \times 10^{-19}$ and 1.0×10^{-90} , respectively; Figures S3F, S3J, and S3K). These cross-validated IGF2BP3 targets encode proteins with functions in cellular adhesion, migration, and remodeling of the extracellular matrix (Figure S3G).

IGF2BP3-RNA crosslinks overlap miRNA target sites in 3' UTRs. We determined if IGF2BP3 shares sequence specificity with miRNAs. We scored 221 miRNA seed-target site pairings (Lewis et al., 2005) by their similarity to IGF2BP3-bound pentamers (see Experimental Procedures). miRNAs score significantly higher if their target site crosslinks to IGF2BP3 than isolated sites (Figure 3A; Table S8; $p < 0.00153$, Wilcoxon rank-sum test). Specific miRNA target sites are overrepresented in both the




Figure 4. IGF2BP3 Alters mRNA Association with RISC

(A) Western blot of Ago2 immunoprecipitation from control (NT) or IGF2BP3-depleted (KD) PANC1 cells.

(B–F) qRT-PCR analysis of RNA precipitated with α -Ago2 or nonspecific rabbit IgG (Ago2 RIP or IgG RIP, respectively). Relative quantification for each transcript was performed using 18S rRNA as a reference gene. Statistical significance was estimated for each comparison using an unpaired t test (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).

iCLIP data and within the 3' UTRs of differentially expressed transcripts in PANC1 cells (Figure 3A, gray boxes; Figures S3H and S3I; Tables S9 and S10). These include *miR-1*, *-9*, *-17*, *-20A/B*, *-19A/B*, *-106*, *-128A/B*, *-181*, *-200B/C*, *-429*, and *-506*, among others. Small RNA-seq confirmed the expression of this subset of miRNA in PANC1 cells (Figure 3B; Table S11).

RBP can stabilize mRNA by competing with miRNAs for common regulatory motifs (Jens and Rajewsky, 2015). To test this hypothesis, we re-examined IGF2BP3-dependent changes in steady-state mRNA levels. Transcripts targeted by both IGF2BP3 and miRNAs tended toward a reduction in steady state mRNA levels. By contrast, transcripts containing only miRNA-target sites were largely unaffected by IGF2BP3 depletion (Figure S3I). These data suggest that IGF2BP3 may attenuate miRNA-mediated mRNA decay. To further determine if IGF2BP3 antagonizes specific miRNAs, we generated luciferase mRNA reporters containing exact matches to *miR-9* and *-128* in their 3' UTR (Figure 3C). Both miRNAs target a sequence predicted to bind IGF2BP3. If the attenuation model is correct, we predict IGF2BP3-depletion would result in a significant decrease in luciferase reporter expression. In wild-type cells, both *miR-9* and *-128* reporters showed significant repression relative to the control reporter construct (Figure 3D; $p < 0.0022$). By contrast, repression of *miR-9* and *-128* luciferase reporters was significantly attenuated in IGF2BP3-depleted cells (Figure 3D, compare repression of *miR-9* and *-128* in IGF2BP3-depleted or control cells; $p < 0.0022$).

IGF2BP3 Promotes Ago2-mRNA Interactions

The data presented above suggest that IGF2BP3 may function in concert with the RISC in PDAC cells. We tested this hypothesis by immunoprecipitating Argonaute 2 (Ago2), a RISC component (Gerstein et al., 2010), from control or IGF2BP3-depleted PANC1 cells and further quantified co-purified mRNA by qRT-PCR. Western blotting confirmed precipitation of Ago2 from both control and IGF2BP3-depleted cells (Figure 4A). *TBP* and *HMGA2* mRNAs served as controls for this experiment. *TBP* mRNA was not detected in any of the IGF2BP3 protein-RNA interaction assays (iCLIP or RIP), and its steady-state mRNA levels are not affected by IGF2BP3 depletion (Figure S4). By contrast, *HMGA2* is a bona fide IGF2BP3-regulatory target. IGF2BP3 stabilizes *HMGA2* mRNA by antagonizing its association with RISC (Jonson et al., 2014). Besides *HMGA2*, we selected several other IGF2BP3-bound transcripts for analysis including *ZFP36L1*, *DCBLD2*, and *CLDN1*. IGF2BP3 depletion correlates with increased *ZFP36L1*, *DCBLD2*, and *CLDN1* mRNA levels and decreased *HMGA2* mRNA (Figure S4). All the mRNAs co-precipitate with Ago2 from both control and knockdown cells (Figure 4, compare Ago2-RIP to immunoglobulin G [IgG]). *TBP* mRNA binding to Ago2 was independent of IGF2BP3 protein levels

(Figure 4B). As expected, *HMGA2* mRNA co-precipitation with Ago2 increased in IGF2BP3-depleted cells (Figure 4C). However, Ago2's association with *ZFP36L1*, *DCBLD2*, and *CLDN1* mRNAs diminished. (Figures 4D–4F; $p < 0.0161$, 0.0135 and 0.0144 , respectively). These data show that IGF2BP3 is a bimodal modulator of the RISC-mRNA association.

DISCUSSION

In this study, we identify a set of IGF2BP3 mRNA targets enriched in cancer-related pathways including focal adhesions, adherens junctions, actin-cytoskeleton, and cell migration. The IGF2BP3 RNA regulon reported here is strikingly similar to the homologous *Drosophila* protein IMP (dIMP) (Hansen et al., 2015). Our study provides evidence that IGF2BP3 and miRNAs converge on the 3' UTRs of target transcripts to coordinately up- and downregulate programs of gene expression that are associated with malignancy and invasiveness. The results further show that this dual activity of IGF2BP3 likely operates through its ability to protect transcripts from, or enhance, miRNA-mediated post-transcriptional gene silencing.

The expression of IGF2BP3 correlates with malignancy. Elucidating direct IGF2BP3-mRNA targets is a major challenge for the field (Bell et al., 2013). Earlier studies identified thousands of IGF2BP3 targets using highly sensitive assays with low specificity (Taniuchi et al., 2014; Hafner et al., 2010). Here, we delineate a refined set of mRNA targets by integrating different genomic approaches. A similar strategy significantly reduced the mRNA target space for HuR and hnRNP H1 (Uren et al., 2016; Mukherjee et al., 2011). This integrated approach to elucidating IGF2BP3 target transcripts was also applied to human B-ALL cells (Palanichamy et al., 2016). We identified a regulon of similar size (216 transcripts in B-ALL cells versus 164 in PDAC cells) but with very different classes of enriched transcripts such as cell-cycle regulation and blood cell differentiation (Palanichamy et al., 2016). Further, a significant fraction (~65%) of the B-ALL targets are downregulated upon IGF2BP3 depletion. These data suggest a role for IGF2BP3 in mRNA stabilization in B-ALL cells. It will be interesting to determine how IGF2BP3 activities are defined in different cell types.

miRNA modulation is a major function of RBPs (Ho et al., 2013; Kundu et al., 2012; Kedde et al., 2007; Jafarifar et al., 2011; Bhat-tacharyya et al., 2006; Jing et al., 2005; Xue et al., 2013). IGF2BP3 promotes mRNA stability, as described for *CD44* and *HMGA2* (Vikesaa et al., 2006; Jønson et al., 2014). One mechanism suggested by Jønson et al., and partially supported by our iCLIP data, is that in certain contexts miRNAs and IGF2BP3 compete for common binding sites within 3' UTRs. The sequence similarity between the consensus IGF2BP3 RNA recognition elements and target sites of several different miRNA families support this hypothesis (Figure 3) as does the concomitant decrease in expression of mRNAs that are targeted by both regulatory systems (Figure S3I). However, our miRNA reporters and Ago2 RIP experiments revealed an unexpected role for IGF2BP3 in promoting the association of mRNAs with Ago2 (Figures 3D and 4). The mechanism we propose here is consistent with a recent finding that IGF2BP3 destabilizes the *EIF4EBP2* mRNA in HeLa cells (Mizutani et al., 2015).

Our results demonstrate that IGF2BP3 is a bi-modal regulator of target mRNA stability. It remains to be determined how the dual roles of IGF2BP3 in mRNA stability are regulated and if IGF2BP3 has different functions in different types of cancer cells. Other RBPs, including HuR, PTB, MOV10, and FMRP, function as bi-modal modulators of RISC function (Kenny et al., 2014; Kim et al., 2009; Kundu et al., 2012; Mukherjee et al., 2011; Young et al., 2012; Xue et al., 2013). Given that several of the miRNA families presented in Figure 3C play roles in cancer cell biology, it is possible that the modulation of RISC by IGF2BP3 contributes to PDAC pathogenesis.

EXPERIMENTAL PROCEDURES

Cell Lines and Constructs

We maintained PDAC cell lines, PL45 and PANC1, according to the recommended conditions (ATCC). We created independent clones of IGF2BP3-depleted or control cell lines by transfecting PDAC cells with plasmids that express *IGF2BP3*-targeting short hairpin RNA or a non-targeting control (Santa Cruz Biotechnology) with Lipofectamine 2000 (Life Technologies) and selecting with puromycin (1 μ g/ml).

Western Blot and Antibodies

We performed western blotting as previously described (Sterne-Weiler et al., 2011). We probed nitrocellulose filters with the following antibodies against IGF2BP3 (clone D7, Santa Cruz), GAPDH (clone FL335, Santa Cruz), hnRNP A1 (clone 4B10, Santa Cruz), and anti-4EBP (clone D-10, Santa Cruz).

Immunofluorescence Microscopy

Cells grown on acid-washed, fibronectin-coated coverslips were fixed in 4% paraformaldehyde in PBS for 15 min and washed in PBS for 10 min and 0.15 M glycine in PBS for 10 min on a shaker. Cells were permeabilized in 0.02% Triton in PBS for 10 min with a subsequent wash in PBS for another 10 min. Coverslips were blocked using 10% serum (to secondary host animal) in PBS and incubated with primary antibodies (anti-FAK [C-20, Santa Cruz] and anti-IGF2BP3 [N-19, Santa Cruz]) diluted in 5% serum in a humidified chamber for 12 hr at 4°C. After three washes in PBS for 15 min each, the samples were incubated with secondary antibody and a nuclear stain diluted in 5% serum for 45 min in a humidified chamber at room temperature. All samples were mounted onto slides with Fluoromount-G (Southern Biotech) and allowed to dry overnight. Slides were imaged on Keyence Biorevo BZ-9000 digital widefield microscope.

Invasion Assay

In vitro invasion assay used transwell inserts with 8.0- μ m pore size according to the manufacturer's protocol (BD Biosciences). Each transwell insert (Matrigel coated or control) received 5×10^5 PDAC cells suspended in serum-free medium. The transwell inserts were then placed into six-well plates containing medium supplemented with 10% FBS. After 72 hr, we removed cells from the upper surface of the transwell inserts and fixed/stained cells on the lower surface using the Quik-Diff kit and DAPI (IMEB). We counted DAPI stained nuclei from four fields of each well using an inverted microscope and ImageJ software. We performed each experiment in triplicate.

Gene Expression Profiling of PDAC Cells by RNA-Seq

We isolated RNA from cytosolic fractions of IGF2BP3-depleted or control PANC1 and PL45 cells using TRI-Reagent LS (Sigma). Illumina-compatible sequencing libraries were prepared using the NEXTflex Rapid Directional qRNA-Seq Kit (BIO Scientific). We analyzed each condition in duplicate using the HiSeq2500 platform. miRNA expression was profiled in PANC1 cells using the NEXTflex small RNA-seq kit v2 (BIO Scientific). miRNA expression was analyzed in triplicate. Mapping statistics can be found in Table S12.

RIP-Seq Assay

RNA immunoprecipitation with anti-IGF2BP3 (RN009P, MBL) or normal rabbit IgG (AB-105-C, R&D Systems) was performed with PL45 and PANC1 cells as

previously described (Uren et al., 2016). Each RIP and control immunoprecipitation was performed in duplicate (PL45) or triplicate (PANC1). Mapping statistics can be found in Table S12.

iCLIP Assay

iCLIP was performed as previously described using PL45 and PANC1 cells (König et al., 2010). Two replicate experiments were performed in PL45 cells and one experiment was performed in PANC1. The three datasets were pooled for analysis. Mapping statistics can be found in Table S12.

cDNA Synthesis and qRT-PCR

cDNA was synthesized from RNA purified from cytosolic extracts and RIP samples using the high-capacity cDNA reverse transcriptase kit from ABI Scientific. qPCR was performed using a Roche Lightcycler 480 (Roche Diagnostics), Titanium Taq (Clontech Laboratories), and SYBR green dye. Based on melting point analysis, primers corresponding to *TBP1*, *CLDN1*, *ZFP36L1*, *DCBDL2*, *FAT1*, *DSG2*, *TFF12*, *GJA1*, *HMG2*, *IGF2BP3*, and *18S* rRNA generated a single specific amplicon. Primer sequences can be found in Supplemental Experimental Procedures. For normalization, *TBP* was used as a reference gene for comparisons in cytoplasmic RNA, whereas *18S* rRNA was used in the RIP experiments. To compare *TBP* levels between cells, the geometric mean of three stable genes (*CFL1*, *RHOA*, and *EGFR*) was used as a reference. Relative expression levels were determined using the $\Delta\Delta CT$ method with the Roche Lightcycler Analysis Software Package version 1.5 (Roche Diagnostics). All experiments use a minimum of three technical replicates per sample and at least three biological replicates per analysis. Statistical significance was determined by comparing the mean normalized ratios of each mRNA using a non-parametric Mann-Whitney *U* test (Prism6, GraphPad Software).

Ago2 RNA Immunoprecipitation

To immunoprecipitate Ago2 mouse monoclonal antibody 9E8.2 (Millipore) was tethered to Dynal protein A beads using a rabbit anti-mouse IgG bridging antibody (Jackson ImmunoResearch, Fc γ Fragment Specific). Mouse IgG (Pierce Biotechnology) was used as a negative control for RIP assays. Beads were washed three times in lysis buffer (25 mM Tris-HCl [pH 8.0], 150 mM NaCl, 2 mM MgCl₂, 0.5% NP-40, and 5 mM DTT) to remove the unbound antibody. Whole-cell extracts were prepared from IGF2BP3-depleted or control PANC1 cells by lysing cells on ice for 10 min in 1 ml fresh lysis buffer with protease inhibitors (Complete Protease Inhibitor Cocktail Tablets, EDTA-free, Roche Applied Science) and RNasin (1/1,000 dilution; Applied Biosystems), followed by sonication and centrifugation at 10,000 \times g for 10 min. Following the washes in lysis buffer (as described in Supplemental Experimental Procedures), beads were treated with 5 U RQ DNase I (Promega) for 10 min at 37°C. An aliquot from each immunoprecipitation was used for western blot analysis, and RNA was purified from the remainder using TRIzol LS (Invitrogen). Total RNA from cell lysates was isolated using the same procedure and was also subjected to DNA digestion as described above prior to cDNA synthesis.

iCLIP, RIP, mRNA, and miRNA-Seq Data Analysis Pipeline

Bioinformatic analyses are described in Supplemental Experimental Procedures.

Luciferase Reporter Assays

Luciferase reporters (pMIR, Life Scientific) containing sequences with perfect complementarity to miR-9 and -128 in their 3'UTR were transfected into control or IGF2BP3-depleted PANC1 cells using Lipofectamine 2000 (Life Scientific). Renilla luciferase reporter plasmid (Promega) was cotransfected as a control for transfection efficiency. Renilla and firefly luciferase activity was assayed 24 hr post-transfection using the Dual-Glo system (Promega).

ACCESSION NUMBERS

The accession number for the RNA-seq data reported in this paper is available in the NCBI GEO SRA: GSE79147.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, four figures, and 12 tables and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2016.04.083>.

AUTHOR CONTRIBUTIONS

H.E., J.M.H., T.S.-W., and J.R.S. designed and performed experiments, analyzed data, prepared figures, and prepared the manuscript; D.J.C., M.D., J.M.D., A.W., and O.C. performed experiments and analyzed data; P.J.U. and S.K. analyzed data; F.J., S.C.B., and M.Q. performed experiments; L.H., A.D.S., L.O.F.P., and M.M.T. designed experiments and prepared the manuscript; and B.J.B. edited the manuscript.

ACKNOWLEDGMENTS

This work was funded by the National Institutes of Health (NIH) through grants GM109146 (to J.R.S.), HG007336 (to M.M.T.), and HG006015 (to A.D.S. and L.O.F.P.); the Santa Cruz Cancer Benefit Group (to J.R.S.); the University of California Cancer Research Coordinating Committee (to J.R.S.) and CIRM grant TG2-00157 (to H.E.); CIRM Major Facilities grant FA1-00617-1; and CIRM Shared Stem Cell Facilities grant CL1-00506-1.2. T.S.-W. was supported in part by an operating grant from the Canadian Institutes of Health Research and a CH Best Foundation Postdoctoral Fellowship. We thank The Genome Sequencing and Analysis Facility at the University of Texas at Austin.

Received: May 16, 2015

Revised: February 8, 2016

Accepted: April 21, 2016

Published: May 19, 2016

REFERENCES

- Bell, J.L., Wächter, K., Mühleck, B., Pazaitis, N., Köhn, M., Lederer, M., and Hüttelmaier, S. (2013). Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? *Cell. Mol. Life Sci.* **70**, 2657–2675.
- Bhattacharyya, S.N., Habermacher, R., Martine, U., Closs, E.I., and Filipowicz, W. (2006). Relief of microRNA-mediated translational repression in human cells subjected to stress. *Cell* **125**, 1111–1124.
- Blackinton, J.G., and Keene, J.D. (2014). Post-transcriptional RNA regulons affecting cell cycle and proliferation. *Semin. Cell Dev. Biol.* **34**, 44–54.
- Chao, J.A., Patskovsky, Y., Patel, V., Levy, M., Almo, S.C., and Singer, R.H. (2010). ZBP1 recognition of beta-actin zipcode induces RNA looping. *Genes Dev.* **24**, 148–158.
- Findeis-Hosey, J.J., and Xu, H. (2011). The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. *Hum. Pathol.* **42**, 303–314.
- Gerstberger, S., Hafner, M., and Tuschl, T. (2014). A census of human RNA-binding proteins. *Nat. Rev. Genet.* **15**, 829–845.
- Gerstein, M.B., Lu, Z.J., Van Nostrand, E.L., Cheng, C., Arshinoff, B.I., Liu, T., Yip, K.Y., Robilotto, R., Rechtsteiner, A., Ikegami, K., et al.; modENCODE Consortium (2010). Integrative analysis of the *Caenorhabditis elegans* genome by the modENCODE project. *Science* **330**, 1775–1787.
- Glorian, V., Maillot, G., Polès, S., Iacovoni, J.S., Favre, G., and Vagner, S. (2011). HuR-dependent loading of miRNA RISC to the mRNA encoding the Ras-related small GTPase RhoB controls its translation during UV-induced apoptosis. *Cell Death Differ.* **18**, 1692–1701.
- Gu, W., Katz, Z., Wu, B., Park, H.Y., Li, D., Lin, S., Wells, A.L., and Singer, R.H. (2012). Regulation of local expression of cell adhesion and motility-related mRNAs in breast cancer cells by IMP1/ZBP1. *J. Cell Sci.* **125**, 81–91.
- Hafner, M., Landthaler, M., Burger, L., Khorshid, M., Hausser, J., Berninger, P., Rothballer, A., Ascano, M., Jr., Jungkamp, A.C., Munschauer, M., et al. (2010).

- Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. *Cell* **141**, 129–141.
- Hansen, H.T., Rasmussen, S.H., Adolph, S.K., Plass, M., Krogh, A., Sanford, J., Nielsen, F.C., and Christiansen, J. (2015). Drosophila Imp iCLIP identifies an RNA assemblage coordinating F-actin formation. *Genome Biol.* **16**, 123.
- Ho, J.J., Robb, G.B., Tai, S.C., Turgeon, P.J., Mawji, I.A., Man, H.S., and Marsden, P.A. (2013). Active stabilization of human endothelial nitric oxide synthase mRNA by hnRNP E1 protects against antisense RNA and microRNAs. *Mol. Cell. Biol.* **33**, 2029–2046.
- Jafarifar, F., Yao, P., Eswarappa, S.M., and Fox, P.L. (2011). Repression of VEGFA by CA-rich element-binding microRNAs is modulated by hnRNP L. *EMBO J.* **30**, 1324–1334.
- Jens, M., and Rajewsky, N. (2015). Competition between target sites of regulators shapes post-transcriptional gene regulation. *Nat. Rev. Genet.* **16**, 113–126.
- Jing, Q., Huang, S., Guth, S., Zarubin, T., Motoyama, A., Chen, J., Di Padova, F., Lin, S.C., Gram, H., and Han, J. (2005). Involvement of microRNA in AU-rich element-mediated mRNA instability. *Cell* **120**, 623–634.
- Jønson, L., Christiansen, J., Hansen, T.V., Vikeså, J., Yamamoto, Y., and Nielsen, F.C. (2014). IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development. *Cell Rep.* **7**, 539–551.
- Kedde, M., Strasser, M.J., Boldajipour, B., Oude Vrielink, J.A., Slanchev, K., le Sage, C., Nagel, R., Voorhoeve, P.M., van Duijse, J., Ørom, U.A., et al. (2007). RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. *Cell* **131**, 1273–1286.
- Keene, J.D. (2007). RNA regulons: coordination of post-transcriptional events. *Nat. Rev. Genet.* **8**, 533–543.
- Kenny, P.J., Zhou, H., Kim, M., Skariah, G., Khetani, R.S., Drnevich, J., Arcila, M.L., Kosik, K.S., and Ceman, S. (2014). MOV10 and FMRP regulate AGO2 association with microRNA recognition elements. *Cell Rep.* **9**, 1729–1741.
- Kim, H.H., Kuwano, Y., Srikantan, S., Lee, E.K., Martindale, J.L., and Gorospe, M. (2009). HuR recruits let-7/RISC to repress c-Myc expression. *Genes Dev.* **23**, 1743–1748.
- Köbel, M., Xu, H., Bourne, P.A., Spaulding, B.O., Shih, IeM., Mao, T.L., Soslow, R.A., Ewanowich, C.A., Kalloger, S.E., Mehl, E., et al. (2009). IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. *Mod. Pathol.* **22**, 469–475.
- König, J., Zarnack, K., Rot, G., Curk, T., Kayikci, M., Zupan, B., Turner, D.J., Luscombe, N.M., and Ulne, J. (2010). iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. *Nat Struct Mol Biol.* **17**, 909–915.
- Kundu, P., Fabian, M.R., Sonenberg, N., Bhattacharyya, S.N., and Filipowicz, W. (2012). HuR protein attenuates miRNA-mediated repression by promoting miRISC dissociation from the target RNA. *Nucleic Acids Res.* **40**, 5088–5100.
- Lewis, B.P., Burge, C.B., and Bartel, D.P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **120**, 15–20.
- Lochhead, P., Imamura, Y., Morikawa, T., Kuchiba, A., Yamauchi, M., Liao, X., Qian, Z.R., Nishihara, R., Wu, K., Meyerhardt, J.A., et al. (2012). Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. *Eur. J. Cancer* **48**, 3405–3413.
- Mizutani, R., Imamachi, N., Suzuki, Y., Yoshida, H., Tochigi, N., Oonishi, T., Suzuki, Y., and Akimitsu, N. (2015). Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA. *Oncogene*, Published online November 2, 2015. <http://dx.doi.org/10.1038/onc.2015.410>.
- Mueller, F., Bommer, M., Lacher, U., Ruhland, C., Stagge, V., Adler, G., Gress, T.M., and Seufferlein, T. (2003). KOC is a novel molecular indicator of malignancy. *Br. J. Cancer* **88**, 699–701.
- Mueller-Pillasch, F., Pohl, B., Wilda, M., Lacher, U., Beil, M., Wallrapp, C., Haemeister, H., Knöchel, W., Adler, G., and Gress, T.M. (1999). Expression of the highly conserved RNA binding protein KOC in embryogenesis. *Mech. Dev.* **88**, 95–99.
- Mukherjee, N., Corcoran, D.L., Nusbaum, J.D., Reid, D.W., Georgiev, S., Hafner, M., Ascano, M., Jr., Tuschl, T., Ohler, U., and Keene, J.D. (2011). Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. *Mol. Cell* **43**, 327–339.
- Nielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A.H., Wewer, U.M., and Nielsen, F.C. (1999). A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. *Mol. Cell. Biol.* **19**, 1262–1270.
- Palanichamy, K., Tran, T.M., Howard, J.M., Contreras, J.R., Fernando, T.R., Sterne-Weiler, T., Katzman, S., Toloue, M., Yan, W., Basso, G., et al. (2016). Hematopoietic progenitor proliferation is promoted by the RNA-binding protein IGF2BP3. *J. Clin. Invest.* **126**, 1495–1511.
- Ryu, B., Jones, J., Blades, N.J., Parmigiani, G., Hollingsworth, M.A., Hruban, R.H., and Kern, S.E. (2002). Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. *Cancer Res.* **62**, 819–826.
- Schaeffer, D.F., Owen, D.R., Lim, H.J., Buczkowski, A.K., Chung, S.W., Scudamore, C.H., Huntsman, D.G., Ng, S.S., and Owen, D.A. (2010). Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. *BMC Cancer* **10**, 59.
- Sterne-Weiler, T., Howard, J., Mort, M., Cooper, D.N., and Sanford, J.R. (2011). Loss of exon identity is a common mechanism of human inherited disease. *Genome Res.* **21**, 1563–1571.
- Stoskus, M., Gineikiene, E., Valcekiene, V., Valatkaite, B., Pileckyte, R., and Griskevicius, L. (2011). Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities. *Blood Cells Mol. Dis.* **46**, 321–326.
- Suvasini, R., Shruti, B., Thota, B., Shinde, S.V., Friedmann-Morvinski, D., Nawaz, Z., Prasanna, K.V., Thennarasu, K., Hegde, A.S., Arivazhagan, A., et al. (2011). Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. *J. Biol. Chem.* **286**, 25882–25890.
- Taniuchi, K., Furihata, M., Hanazaki, K., Saito, M., and Saibara, T. (2014). IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer. *Oncotarget* **5**, 6832–6845.
- Uren, P.J., Bahrami-Samani, E., Burns, S.C., Qiao, M., Karginov, F.V., Hodges, E., Hannon, G.J., Sanford, J.R., Penalva, L.O., and Smith, A.D. (2012). Site identification in high-throughput RNA-protein interaction data. *Bioinformatics* **28**, 3013–3020.
- Uren, P.J., Bahrami-Samani, E., De Araujo, P.R., Vogel, C., Qiao, M., Burns, S.C., Smith, A.D., and Penalva, L.O. (2016). High-throughput analyses of hnRNP H1 dissects its multi-functional aspect. *RNA Biol.* **13**, 400–411.
- Vikesaa, J., Hansen, T.V., Jønson, L., Borup, R., Wewer, U.M., Christiansen, J., and Nielsen, F.C. (2006). RNA-binding IMPs promote cell adhesion and invadopodia formation. *EMBO J.* **25**, 1456–1468.
- Wagner, M., Kunsch, S., Duerschmied, D., Beil, M., Adler, G., Mueller, F., and Gress, T.M. (2003). Transgenic overexpression of the oncofetal RNA binding protein KOC leads to remodeling of the exocrine pancreas. *Gastroenterology* **124**, 1901–1914.
- Xue, Y., Ouyang, K., Huang, J., Zhou, Y., Ouyang, H., Li, H., Wang, G., Wu, Q., Wei, C., Bi, Y., et al. (2013). Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. *Cell* **152**, 82–96.
- Yaniv, K., and Yisraeli, J.K. (2002). The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. *Gene* **287**, 49–54.
- Young, L.E., Moore, A.E., Sokol, L., Meisner-Kober, N., and Dixon, D.A. (2012). The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. *Mol. Cancer Res.* **10**, 167–180.
- Zhang, L., Lee, J.E., Wilusz, J., and Wilusz, C.J. (2008). The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. *J. Biol. Chem.* **283**, 22457–22463.